Destiny Pharma (DEST) Receives “Corporate” Rating from FinnCap

FinnCap reaffirmed their corporate rating on shares of Destiny Pharma (LON:DEST) in a report released on Thursday. FinnCap currently has a GBX 250 ($3.53) price target on the stock.

Shares of DEST stock traded down GBX 2.90 ($0.04) during mid-day trading on Thursday, hitting GBX 126.10 ($1.78). The stock had a trading volume of 13,000 shares, compared to its average volume of 4,205. Destiny Pharma has a fifty-two week low of GBX 111 ($1.57) and a fifty-two week high of GBX 235 ($3.32).

Destiny Pharma (LON:DEST) last announced its quarterly earnings data on Thursday, April 12th. The company reported GBX (8.40) (($0.12)) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (8.30) (($0.12)) by GBX (0.10) ($0.00).



ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/13/destiny-pharma-dest-receives-corporate-rating-from-finncap.html.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the development of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply